The Eye Drop That Refuses to Blink Away

Most eye drops have the same problem, and it is not the ingredients. It is the clock. You blink, and within minutes the relief is gone. So you reach for the bottle again. And again - six, eight, sometimes twelve times a day. EternaTear, a small company in Raleigh, North Carolina, was built on a stubborn idea about that clock: that the winning artificial tear is not the one with a cleverer molecule, but the one that simply refuses to leave your eye.

The company and its lead product share a name. EternaTear - both the startup and the drop - is an over-the-counter, preservative-free artificial tear formulated to supplement all layers of the eye's tear film and, by the company's account, remain on the ocular surface two to four times longer than the best OTC products currently on the shelf. The pitch is almost contrarian in a market obsessed with new actives: the main feature is that you use it less.

The founder

A second act on the surface of the eye

EternaTear was founded in 2018 by Tim Willis, who has spent more than 15 years working on one narrow, unglamorous piece of anatomy: the wet film on the front of the human eye. That resume is unusual. Willis helped develop Soothe XP, an artificial tear now marketed by Bausch & Lomb, and helped develop and license Systane Balance to Alcon - which means two of his own past products now sit on the same shelf he is trying to disrupt.

He also co-founded and led TearScience, a dry-eye company that raised roughly $134 million before being acquired by Johnson & Johnson in 2017. Willis is listed as a Fellow of the American Academy of Optometry with a background in electro-mechanical engineering - an operator who knows both the science and the exit.

The problem

The reapplication treadmill

Dry eye is not rare and it is not trivial. The company cites roughly 320 million people worldwide living with it - the burning, itching, grittiness and light sensitivity that can quietly erode quality of life. The standard consumer fix is a bottle of lubricating drops that has to be reapplied many times a day, because conventional tears wash out of the eye quickly. For moderate, chronic sufferers, that is less a treatment than a chore attached to a schedule.

EternaTear reframes that chore as the opportunity. Instead of competing on which active ingredient soothes best in the first thirty seconds, the company built its thesis around duration - what it describes as a "previously unrecognized mechanism" that keeps the tear on the eye longer. Fewer drops, fewer interruptions, more of the day spent not thinking about your eyes.

There is a practical texture to who this is for. Think of the office worker staring at a screen through a dry afternoon, the contact-lens wearer whose eyes give out by evening, the older adult whose tear production has quietly declined with age. For all of them the value proposition is the same and it is measured in interruptions avoided: a drop that does its job while they are in a meeting, on a drive, or asleep, rather than one that demands attention on the hour. The product's preservative-free formulation matters here too - frequent users of preserved drops can develop irritation from the preservatives themselves, so a preservative-free tear that is also used less often compounds the benefit.

The market

How it plans to be different

The dry-eye aisle is crowded and well defended. On the OTC side sit Systane from Alcon, Refresh from Allergan/AbbVie, Blink, and Bausch & Lomb's Soothe line; on the prescription side, therapies like Restasis and Xiidra. EternaTear is not trying to out-ingredient any of them. It is trying to out-last them, then sell that difference at the counter without a prescription - preservative-free, over-the-counter, and, eventually, one click away on an e-commerce shelf.

The over-the-counter path is a deliberate business choice, not just a scientific one. A prescription product means clinics, payers, sales reps and prior authorizations; an OTC tear means a box on a shelf and a product page a consumer can buy directly. That points EternaTear toward a direct-to-consumer and retail model - the kind of business where a good duration claim, once cleared, becomes a marketing line customers can feel the first week they switch. It also keeps the company light: no field sales army, just a formulation, a label, and a channel.

There is geography working in its favor. Raleigh sits inside North Carolina's Research Triangle, a dense cluster of universities, contract research organizations and life-sciences talent, with the North Carolina Biotechnology Center helping surface companies like this one. For a founder assembling clinical, regulatory and manufacturing partners around a small core team, being in that ecosystem is less scenery than infrastructure.

The money

An oversubscribed round, and an honest goal

In October 2020 EternaTear announced a $4.9 million Series A round that came in oversubscribed - co-led by Carolina Angel Network and Keiretsu Forum, with participation from Band of Angels, Deep Work Capital, Duke Angel Network and Keiretsu Capital, alongside strategic ophthalmologists, optometrists and other angels. The stated use of funds was practical: complete a multi-site clinical marketing study and secure U.S. FDA OTC registration, then push toward the US and European markets.

The pitch had an unusually candid ending. In the same announcement, Willis named the objective out loud: driving EternaTear forward "to meet its objectives including, ultimately, a successful market exit." When your last company was bought by J&J, you do not pretend the acquisition is not the plan.

The team

Two on paper, an industry on the board

On paper EternaTear is tiny - a core of about two people. But the surrounding bench is where the story gets interesting. The executive and board roster reads like a reunion of the eye-care industry: a chief technology officer who ran consumer R&D at Alcon/Novartis and launched more than 15 ophthalmic products; a chief marketing officer who once led Allergan's consumer/OTC division; and directors who grew an eye-care US business past $1 billion in annual sales. It is the modern lean-biotech playbook - keep the operating core small, borrow the muscle, and center everything on the founder's obsession.

That structure is also a tell about ambition. You do not assemble that much senior ophthalmic talent for a niche product. You assemble it for a category bet - and to make an eventual acquirer comfortable that the people behind the drop have done this before.

What you can take from it

The lesson hiding in a bottle

For anyone building in a crowded category, EternaTear is a clean case study in wedge-finding. The incumbents own the ingredient conversation, so it did not have that fight. It found the customer's actual, daily annoyance - reapplying all day long - and made the fix the entire product. Duration is harder to copy than a slogan, and it maps directly to something a sufferer feels. Reframe your category around the pain the customer lives with, not the feature the market advertises, and you get a story the giants cannot simply restate.

The caveats are just as instructive. A duration claim only matters if a clinical study backs it and regulators clear it, which is exactly why the round money went toward a marketing study and FDA OTC registration rather than flashier things. It is a plan that works if the science holds, the label is earned, and consumers are willing to switch bottles - and one that would not work if any of those three links break. That is the honest shape of an early-stage consumer-health bet: a sharp idea, a credible team, and a road that still runs through the lab and the FDA before it reaches your medicine cabinet.